|Systematic (IUPAC) name|
|[[Regulation of therapeutic goods |Template:Engvar data]]|
|Metabolism||Hepatic via CYP3A4|
|Biological half-life||1.8 (± 0.4) hours|
|ATC code||J05AE02 (WHO)|
|Molar mass||613.79 g/mol[[Script error: No such module "String".]]|
The Food and Drug Administration (FDA) approved indinavir March 13, 1996, making it the eighth approved antiretroviral. Indinavir was much more powerful than any prior antiretroviral drug; using it with dual NRTIs set the standard for treatment of HIV/AIDS and raised the bar on design and introduction of subsequent antiretroviral drugs. Protease inhibitors changed the very nature of the AIDS epidemic from one of a terminal illness to a somewhat manageable one.
Unfortunately, indinavir wears off quickly after dosing and therefore requires dosing very precisely every eight hours in order to thwart HIV from forming drug resistant mutations including resistances to other protease inhibitors. It has restrictions on what sorts of food may be eaten concurrently.
Side effects include
- Kidney stones
- Metabolic abnormalities including hyperlipidemia (cholesterol or triglyceride elevations)
- alterations in body shape known as lipodystrophy
|50px||This antiinfective drug article is a stub. You can help ssf by expanding it.|